This week on LATAM MedTech Insights, we dive into the significant new regulatory guidance from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). This update brings Brazil closer to global standards but introduces critical new challenges for foreign manufacturers in areas like risk classification, AI validation, and cybersecurity.

We explore the immediate impact on MedTech companies aiming for the Brazilian market. For example, a US-based digital health firm was on the verge of submitting its product for approval. Now, they're confronting the painful reality that their AI algorithm's validation data is insufficient under the new, stricter guidelines, forcing them into a costly and time-consuming redevelopment cycle just to meet compliance. This episode unpacks how to anticipate and navigate these exact scenarios.

Key Takeaways:

- What are the three most critical changes in ANVISA's new SaMD framework?

- How will the new risk classifications impact your product's path to market?

- Are your cybersecurity measures compliant with both ANVISA's new rules and Brazil's LGPD?

- What new clinical evidence is required for AI and machine learning-driven SaMD?

- How can you leverage your existing international dossiers for the new submission process?

- Why might your previous go-to-market strategy for Brazil now be obsolete?

- What is the single biggest mistake companies make when interpreting new ANVISA guidance?

Navigating evolving regulatory landscapes is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local experts and advanced AI tools to streamline market access in over 30 countries, including Brazil. From regulatory strategy and dossier submission to acting as your local in-country representative, we turn complexity into clarity. Don't let regulatory hurdles derail your expansion. Contact us at [email protected] or visit https://pureglobal.com to learn more.